hCG (Human Chorionic Gonadotropin) vs Oxandrolone (Anavar)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

hCG (Human Chorionic Gonadotropin)Oxandrolone (Anavar)
CategoryHormonesHormones
Standard DoseResearch indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance.Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.
TimingAdminister on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days.Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.
Cycle DurationOngoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery.Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.
Evidence Levelstrong_humanstrong_human

Mechanism

hCG mimics luteinizing hormone (LH) by binding the LH/CG receptor on testicular Leydig cells, activating the cAMP-PKA signaling cascade that upregulates steroidogenic acute regulatory protein (StAR) and CYP11A1, driving cholesterol conversion to pregnenolone and downstream testosterone synthesis. By maintaining intratesticular testosterone (ITT) levels during exogenous testosterone administration, hCG preserves Leydig cell function, spermatogenesis, testicular volume, and the production of neurosteroids (pregnenolone, DHEA) and estradiol within the testes.

Standard Dosing

Research indicates 250-500 IU administered subcutaneously 2-3 times per week as a TRT adjunct for fertility and testicular maintenance.

Timing

Administer on non-testosterone injection days if using twice-weekly TRT split. Consistent schedule (e.g., Tuesday/Saturday). Refrigerate reconstituted solution; use within 30-60 days.

Cycle Duration

Ongoing for as long as TRT continues and fertility preservation is desired. Can be used in 4-8 week pre-PCT bursts to 'prime' testicular recovery.

Side Effects

  • Elevated estradiol (from intratesticular aromatization)
  • Injection site reactions
  • Headache
  • Gynecomastia (if E2 rises unchecked)
  • Mood swings
  • Potential Leydig cell desensitization at excessive doses (>1500 IU per dose)

Contraindications

  • Androgen-dependent neoplasia (prostate cancer)
  • Precocious puberty
  • hCG-secreting tumors
  • Known hypersensitivity to hCG

Best Stacking Partners

Testosterone Cypionate/Enanthate (primary use as TRT adjunct)Clomiphene (PCT protocol)Anastrozole (if hCG elevates estradiol excessively)

Mechanism

Oxandrolone is a synthetic 17-alpha-alkylated dihydrotestosterone (DHT) derivative with a modified A-ring (replacement of C2 with an oxygen atom) that confers high anabolic-to-androgenic ratio (~10:1). It enhances protein synthesis by activating the androgen receptor while strongly binding sex hormone-binding globulin (SHBG), increasing free testosterone fraction. Oxandrolone directly stimulates phosphocreatine synthesis in skeletal muscle and has demonstrated anti-catabolic effects through cortisol receptor antagonism. In burn patients, it reverses catabolism by restoring the IGF-1/IGFBP-3 axis.

Standard Dosing

Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.

Timing

Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.

Cycle Duration

Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.

Side Effects

  • Hepatotoxicity (dose and duration dependent — mild with therapeutic doses)
  • Lipid profile disruption (significant HDL suppression, LDL elevation)
  • Suppression of endogenous testosterone (dose dependent)
  • Virilization in females at higher doses
  • Headache
  • Nausea
  • Potential hair loss in genetically susceptible individuals

Contraindications

  • Prostate cancer
  • Breast cancer in males
  • Hypercalcemia
  • Severe hepatic impairment or active liver disease
  • Nephrotic syndrome
  • Pregnancy (Category X)

Best Stacking Partners

Testosterone (to maintain hormonal base)BPC-157 (recovery synergy)NAC or TUDCA (liver support)Creatine (synergistic phosphocreatine loading)

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →